Parvus is pioneering a novel class of disease-modifying therapeutics – Navacims™ – that represent a paradigm shift in the way that autoimmune diseases are treated. Current approaches generally require broad suppression of the immune system to prevent immune attack against a patient’s own tissues. In contrast, our Navacim drug candidates are able to selectively blunt the action of pathogenic immune cells (including cytotoxic T cells and antigen-presenting cells), thereby restoring immune tolerance and potentially reversing disease.
Parvus has entered into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture, and commercialize novel Navacim™ therapeutics for the treatment of inflammatory bowel disease (IBD), autoimmune liver diseases (ALD), and celiac disease (CD).
Parvus has shown in multiple preclinical in-vivo models of autoimmune disease that its Navacims can reprogram disease- or tissue-specific cells to orchestrate reversal of disease, as published in leading peer-reviewed journals. Based on the Company’s broadly enabling therapeutic platform, Parvus has generated a robust R&D pipeline and is advancing several proprietary Navacim development candidates toward clinical testing.
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune DiseasesRead More
Parvus Therapeutics Appoints Dr. Curtis Ruegg as Chief Executive OfficerRead More
Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 DiabetesRead More